Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis · Sponsor: Madrigal Pharmaceuticals, Inc.
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
This description comes directly from the study's public registry record.
David Hernandez, MD · 302-640-2217 · dhernandez@madrigalpharma.com
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Not Yet Recruiting |
| University of California Los Angeles Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Not Yet Recruiting |
| Medstar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| The University of Chicago Medicine | Chicago, Illinois, United States | Not Yet Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| University of Nebraska | Omaha, Nebraska, United States | Not Yet Recruiting |
| Northwell Health Inc, Center for Liver Disease and Transplantation | Manhasset, New York, United States | Not Yet Recruiting |
| New York Presbyterian Hospital | New York, New York, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center (VUMC) | Nashville, Tennessee, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07335601